Objectives: The present study aims to evaluate the effect of dapagliflozin on primary
composite outcomes and mortality rate in CKD patients using a systematic review and meta …

Aims Mortality rates from chronic kidney disease (CKD) have increased in the last decade. In
this pre-specified analysis of the DAPA-CKD trial, we determined the effects of dapagliflozin …

Background Chronic kidney disease (CKD) presents a significant clinical and economic
burden to healthcare systems worldwide, which increases considerably with progression …

This meta-analysis was conducted by searching PubMed, Scopus, Cochrane, Ovid till
November 2022 for randomized controlled trials (RCTs) that utilized dapagliflozin 10 mg as …

Abstract Background and Aims Multiple trials have reported that SGLT2 inhibitors reduce the
risk of its primary composite outcome of kidney disease progression or cardiovascular death …

Abstract Background and Aims The SGLT2 inhibitor dapagliflozin reduces the risk of
progressive kidney disease and cardiovascular events in patients with and without type 2 …

Abstract Aims/hypothesis In the Dapagliflozin and Prevention of Adverse Outcomes in
Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive …

Introduction This study aimed to examine the efficacy and safety of dapagliflozin in the
Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) …

Background We compared kidney and cardiorenal protection in patients without type 2
diabetes across urine albumin-creatinine ratio (UACR) levels after initiation on dapagliflozin …

Abstract Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic
Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the …